PILRA

Across TCGA pan-cancer cohorts, PILRA mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PILRA data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PILRA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PILRA expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where PILRA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.287	0.582	.001	33	view →
LSCC	DFS	Median	II,III,IV	1.000	0.830	.003	30	view →
HNSC	DFS	Median	All	1.000	0.900	.039	3	view →
CCRCC	OS	Median	III,IV	0.384	0.919	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PILRA–PDAC (DFS)

Open the PDAC breakdown →